The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 401–500 of 1,000
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Tetraspanins as therapeutic targets in hematological malignancy: a concise review
Beckwith, K. A., Byrd, J. C., & Muthusamy, N. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00091 · Cited by 72
“To mediate ADCC, IgG1 requires covalent attachment of oligosaccharides at Asn297 within its Fc region, but eliminating fucose from this carbohydrate structure is known to improve ADCC (Shinkawa et al., 2003).”
BackgroundInfluentialFc receptors: Cell activators of antibody functions
Rosales, C., & Uribe‐Querol, E. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.44a004 · Cited by 76
“In contrast, IgG antibodies with reduced fucose residues presented higher affinity for human FcRγIIIA and its mouse ortholog FcγRIV and showed improved antibody-dependent cellular toxicity against various tumor cells [61,85,86].”
BackgroundImproving Antibody-Based Cancer Therapeutics Through Glycan Engineering
Yu, X., Marshall, M. J. E., Cragg, M. S., & Crispin, M. (2017) · BioDrugs · doi:10.1007/s40259-017-0223-8 · Cited by 71
Comparison of pain outcomes between two anti‐GD2 antibodies in patients with neuroblastoma
Anghelescu, D. L., Goldberg, J. L., Faughnan, L., Wu, J., Mao, S., Furman, W. L., Santana, V. M., & Navid, F. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25280 · Cited by 65
“18-induced pain in animal models [17] and in the mechanism of hyperalgesia [19].”
BackgroundModulation of antibody effector function
Desjarlais, J. R., & Lazar, G. A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.018 · Cited by 64
Fc Glycans Terminated with N-Acetylglucosamine Residues Increase Antibody Resistance to Papain
Raju, T. S., & Scallon, B. J. (2007) · Biotechnology Progress · doi:10.1021/bp070118k · Cited by 76
Nakano, M., Higo, D., Arai, E., Nakagawa, T., Kakehi, K., Taniguchi, N., & Kondo, A. (2008) · Glycobiology · doi:10.1093/glycob/cwn115 · Cited by 62
“Alpha 1-6 fucosylated biantennary glycans (11), α1-6 fucosylated mono GlcNAc monogalactosyl biantennary glycans (7), and α1-6 fucosylated core five-structure glycan (2) were detected as minor peaks.”
BackgroundInfluentialGlycans – the third revolution in evolution
Lauc, G., Krištić, J., & ZoldoÅ¡, V. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00145 · Cited by 79
Reusch, D., Haberger, M., Kailich, T., Heidenreich, A.-K., Kampe, M., Bulau, P., & Wuhrer, M. (2014) · mAbs · doi:10.4161/mabs.26712 · Cited by 61
“The absence of core fucose results in an increase in antibody-dependent cell-mediated cytotoxicity (ADCC).(12,13) Sialylation may induce anti-inflammatory effects via Th2 signaling and decrease ADCC via reduced interaction with Fcγ receptors.”
BackgroundAnalytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
Lee, K. H., Lee, J., Bae, J. S., Kim, Y. J., Kang, H. A., Kim, S. H., Lee, S. J., Lim, K. J., Lee, J. W., Jung, S. K., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1433976 · Cited by 65
Afucosylated IgG responses in humans – structural clues to the regulation of humoral immunity
Oosterhoff, J. J., Larsen, M. D., van der Schoot, C. E., & Vidarsson, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.08.001 · Cited by 71
“The functional effect on NK cell ADCC in many cases has even exceeded the aforementioned 40-fold affinity increase, most likely due to the increased avidity of the interaction [10,11].”
InfluentialOptimizing Therapeutic Antibody Function: Progress with Fc Domain Engineering
Kaneko, E., & Niwa, R. (2010) · BioDrugs · doi:10.2165/11537830-000000000-00000 · Cited by 69
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential
Duvic, M. A., Evans, M., & Wang, C. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716636541 · Cited by 63
Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
Jacobs, J., Zwaenepoel, K., Rolfo, C. D., den Bossche, J. V., Deben, C., Silence, K., Hermans, C., Smits, E., Schil, P. E. V., Lardon, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3880 · Cited by 63
“ARGX-110, a blocking IgG1 mAb which is currently in a Phase 1b clinical trial, has been developed with enhanced antibody-dependent cellular cytotoxicity (ADCC), endowing the antibody with the ability to deplete CD70 expressing tumor cells as a mode of action additional to its ability to inhibit immune checkpoint funct…”
BackgroundLoss of α1,6-Fucosyltransferase Decreases Hippocampal Long Term Potentiation
Gu, W., Fukuda, T., Isaji, T., Hang, Q., Lee, H.-H., Sakai, S., Morise, J., Mitoma, J., Higashi, H., Taniguchi, N., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.579938 · Cited by 60
“Those studies clearly revealed why a lack of core fucosylation on IgG1 can dramatically enhance antibody-dependent cellular cytotoxicity activity (58, 59).”
BackgroundLoos, A., Droogenbroeck, B. V., Hillmer, S., Grass, J., Kunert, R., Cao, J., Robinson, D. G., Depicker, A., & Steinkellner, H. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2010.00540.x · Cited by 59
Shah, B., Jiang, X. G., Chen, L., & Zhang, Z. (2014) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-014-0858-3 · Cited by 59
“For example, the presence of terminal galactose [15] and bisecting N-acetylglucosamine (GlcNAc) [16, 17], and the absence of core fucose [18, 19], have all been shown to improve antibody effector functions.”
IgG-Fc glycoengineering in non-mammalian expression hosts
Loos, A., & Steinkellner, H. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.05.011 · Cited by 66
Optimization of therapeutic antibodies
Wang, B., Gallolu Kankanamalage, S., Dong, J., & Liu, Y. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab003 · Cited by 57
Tada, M., Ishii‐Watabe, A., Suzuki, T., & Kawasaki, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095787 · Cited by 62
Chemical Synthesis of a Complex-Type N-Glycan Containing a Core Fucose
Nagasaki, M., Manabe, Y., Minamoto, N., Tanaka, K., Silipo, A., Molinaro, A., & Fukase, K. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b02106 · Cited by 64
Antibody engineering for therapeutics
Presta, L. G. (2003) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(03)00103-9 · Cited by 65
Therapeutic Monoclonal Antibodies
Yamada, T. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.37 · Cited by 78
Substrate specificity of FUT8 and chemoenzymatic synthesis of core-fucosylated asymmetric N-glycans
Calderon, A. D., Liu, Y., Li, X., Wang, X., Chen, X., Li, L., & Wang, P. G. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00586a · Cited by 59
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
Koerner, S., Andre, M. C., Leibold, J., Kousis, P. C., Kübler, A., Pal, M., Haen, S. P., Bühring, H.-J., Grosse-Hovest, L., Jung, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.194 · Cited by 56
Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes
Göritzer, K., Maresch, D., Altmann, F., Obinger, C., & Strasser, R. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00121 · Cited by 60
Plant glyco-biotechnology on the way to synthetic biology
Loos, A., & Steinkellner, H. (2014) · Frontiers in Plant Science · doi:10.3389/fpls.2014.00523 · Cited by 62
Mogamulizumab and the Treatment of Ccr4-Positive T-Cell Lymphomas
Remer, M., Al‐Shamkhani, A., Glennie, M. J., & Johnson, P. (2014) · Immunotherapy · doi:10.2217/imt.14.94 · Cited by 59
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells
Nyborg, A. C., Zacco, A., Ettinger, R., Borrok, M. J., Zhu, J., Martin, T., Woods, R., Kiefer, C. M., Bowen, M. A., Cohen, E. S., et al. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.19 · Cited by 58
Glycoprotein production in moss bioreactors
Decker, E. L., & Reski, R. (2011) · Plant Cell Reports · doi:10.1007/s00299-011-1152-5 · Cited by 60
Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS
Liu, S., Cheng, L., Fu, Y., Liu, B., & Liu, X. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.026 · Cited by 58
Chandler, K. B., Mehta, N., Leon, D. R., Suscovich, T. J., Alter, G., & Costello, C. E. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001185 · Cited by 60
Antibody glycosylation: impact on antibody drug characteristics and quality control
Wang, Z., Zhu, J., & Lu, H. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10368-7 · Cited by 67
“However, Shinkawa et al. demonstrated that the most crucial factor for increasing ADCC is the lack of fucose (Shinkawa et al. 2003).”
BackgroundRecent trends in analytical and structural glycobiology
Novotný, M. V., & Alley, W. R. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.05.029 · Cited by 58
“The glycans incorporated into the biopharmaceuticals are known to influence important properties, such as in vivo circulatory half-life and possible antibody-dependent cytotoxicity [13,14].”
BackgroundGlorius, P., Baerenwaldt, A., Kellner, C., Staudinger, M., Dechant, M., Stauch, M. B., Beurskens, F. J. M., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T., et al. (2012) · Leukemia · doi:10.1038/leu.2012.150 · Cited by 56
Using cell engineering and omic tools for the improvement of cell culture processes
Kuystermans, D., Krampe, B., Swiderek, H., & Al-Rubeai, M. (2007) · Cytotechnology · doi:10.1007/s10616-007-9055-6 · Cited by 55
Niwa, R., & Satoh, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24316 · Cited by 61
Self-citationYamaguchi, Y., & Barb, A. W. (2019) · Glycobiology · doi:10.1093/glycob/cwz068 · Cited by 62
Frey, A. D., Karg, S. R., & Kallio, P. T. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00370.x · Cited by 59
A Perspective on the Structure and Receptor Binding Properties of Immunoglobulin G Fc
Hanson, Q., & Barb, A. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00299 · Cited by 68
Lee, J., Kang, H. A., Bae, J. S., Kim, K. D., Lee, K. H., Lim, K. J., Choo, M. J., & Chang, S.-J. (2018) · mAbs · doi:10.1080/19420862.2018.1440170 · Cited by 59
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 60
“Furthermore, afucosylation does not affect binding to FcγRI, C1q, or FcRn.82,83 Importantly, afucosylation enhances ADCC activity regardless of FcγRIIIA polymorphism.84,85 Clinical and Translational Science Several glycoengineered afucosylated mAbs have demonstrated clinic success, the first of which is mogamulizumab,…”
BackgroundInfluentialBobrowicz, M., Fassnacht, C., Ignatova, D., Chang, Y., Dimitriou, F., & Guenova, E. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000509281 · Cited by 59
Lang, P., Barbin, K., Feuchtinger, T. F., Greil, J., Peipp, M., Zunino, S. J., Pfeiffer, M. M., Handgretinger, R., NIETHAMMER, D., & Fey, G. H. (2004) · Blood · doi:10.1182/blood-2003-05-1735 · Cited by 55
Chen, C., Schmilovitz‐Weiss, H., Liu, X., Pappo, O., Halpern, M., Sulkes, J., Braun, M., Cohen, M., Barak, N., Tur‐Kaspa, R., et al. (2009) · Journal of Proteome Research · doi:10.1021/pr800656e · Cited by 60
The Absence of Core Fucose Up-regulates GnT-III and Wnt Target Genes
Kurimoto, A., Kitazume, S., Kizuka, Y., Nakajima, K., Oka, R., Fujinawa, R., Korekane, H., Yamaguchi, Y., Wada, Y., & Taniguchi, N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.502542 · Cited by 56
“Removal of the core fucose from human IgG1 results in a significant enhancement in antibody-dependent cellular cytotoxicity (8), caused by the stronger binding of IgG1 to Fc * This work was supported by RIKEN (the Systems Glycobiology Research”
Konno, Y., Kobayashi, Y., Takahashi, K. L., Takahashi, E., Sakae, S., Wakitani, M., Yamano, K., Suzawa, T., Yano, K., Ohta, T., et al. (2011) · Cytotechnology · doi:10.1007/s10616-011-9377-2 · Cited by 60
“…the antibody Fc region to lymphocyte receptors (FccRs), and is dependent on the content of the fucose attached to the innermost GlcNAc of the N-linked Fc oligosaccharide, so is dramatically enhanced by a reduction in the fucose content (Mori et al. 2007; Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundMethodInfluentialZhang, P., Haryadi, R., Chan, K. F., Teo, G., Goh, J. S. Y., Pereira, N. A., Feng, H., & Song, Z. (2012) · Glycobiology · doi:10.1093/glycob/cws064 · Cited by 52
“…is now widely recognized that the removal of the core fucose from the N-glycans attached to Asn297 of human IgG1 significantly enhances its binding to its receptor, FcγIIIa, and thereby dramatically improves antibody-dependent cellular cytotoxicity (ADCC; Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundMethodYanaka, S., Yagi, H., Yogo, R., Yagi‐Utsumi, M., & Kato, K. (2018) · Journal of Biomolecular NMR · doi:10.1007/s10858-018-0169-2 · Cited by 56
The N-Glycosylation Processing Potential of the Mammalian Golgi Apparatus
Fisher, P., THOMAS‐OATES, J. E., Wood, A. J., & Ungár, D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00157 · Cited by 66
“For example, glycans lacking core fucose (Figure 1A) can increase antibody-dependent cellular cytotoxicity (ADCC) (Shinkawa et al., 2003; YamaneOhnuki et al., 2004).”
Molecular aspects of human FcγR interactions with IgG: Functional and therapeutic consequences
Sibéril, S., Dutertre, C., Boix, C., Bonnin, E., Ménez, R., Stura, E. A., Jorieux, S., Fridman, W. H., & Teillaud, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.05.009 · Cited by 66
Capillary electrophoresis for the analysis of glycoprotein pharmaceuticals
Kamoda, S., & Kakehi, K. (2006) · Electrophoresis · doi:10.1002/elps.200500853 · Cited by 52
The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma
Ishida, T., Ishii, T., Inagaki, A., Yano, H., Kusumoto, S., Ri, M., Komatsu, H., Iida, S., Inagaki, H., & Ueda, R. (2006) · Leukemia · doi:10.1038/sj.leu.2404415 · Cited by 58
In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase
Warnock, D., Bai, X., Autote, K., Gonzales, J., Kinealy, K., Yan, B., Qian, J., Stevenson, T., Zopf, D., & Bayer, R. J. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20658 · Cited by 53
Taniguchi, N., Ohkawa, Y., Maeda, K., Harada, Y., Nagae, M., Kizuka, Y., Ihara, H., & Ikeda, Y. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100905 · Cited by 52
García‐García, A., Serna, S., Yang, Z., Delso, I., Taleb, V., Hicks, T., Artschwager, R., Vakhrushev, S. Y., Clausen, H., Angulo, J., et al. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c01698 · Cited by 56
Zhang, Z., & Shah, B. (2010) · Analytical Chemistry · doi:10.1021/ac102359u · Cited by 51
Glycosylation of Antibody Therapeutics: Optimisation for Purpose
Roy, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-407-0_13 · Cited by 59
Yang, Y., Wang, G., Song, T., Lebrilla, C. B., & Heck, A. J. R. (2017) · mAbs · doi:10.1080/19420862.2017.1290033 · Cited by 52
Subedi, G. P., & Barb, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004998 · Cited by 64
CDG and immune response: From bedside to bench and back
Pascoal, C., Francisco, R., Ferro, T., Ferreira, V. D. R., Jaeken, J., & Videira, P. A. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12126 · Cited by 57
Shrivastava, A., Joshi, S., Guttman, A., & Rathore, A. S. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339828 · Cited by 60
GD2-targeting therapy: a comparative analysis of approaches and promising directions
Philippova, J., Shevchenko, J. A., & Sennikov, S. V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371345 · Cited by 59
Wang, X., Fukuda, T., Li, W., Gao, C., Kondo, A., Matsumoto, A., Miyoshi, E., Taniguchi, N., & Gu, J. (2009) · The Journal of Biochemistry · doi:10.1093/jb/mvp022 · Cited by 53
“This observation indicates that the a1,6-fucose is an important sugar chain for ADCC activity (4, 5).”
BackgroundProtein Glycosylation and Its Impact on Biotechnology
Berger, M., Kaup, M., & Blanchard, V. (2011) · Springer eBooks · doi:10.1007/10_2011_101 · Cited by 57
The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III
Yogo, R., Yamaguchi, Y., Watanabe, H., Yagi, H., Satoh, T., Nakanishi, M., Onitsuka, M., Ōmasa, T., Shimada, M., Maruno, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48323-w · Cited by 56
Glycosylation Alterations in Multiple Sclerosis Show Increased Proinflammatory Potential
Cvetko, A., Kifer, D., Gornik, O., Klarić, L., Visser, E. M., Lauc, G., Wilson, J. F., & Štambuk, T. (2020) · Biomedicines · doi:10.3390/biomedicines8100410 · Cited by 62
Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycans
Stanley, P. (2004) · Glycobiology · doi:10.1093/glycob/cwh136 · Cited by 51
“However, a high content of core fucose in the biantennary N-glycan at Asn 297 correlates with reduced ADCC activity (Shinkawa et al., 2003).”
BackgroundInfluentialSerrato, J. A., Hernandez, V. A., Estrada‐Mondaca, S., Palomares, L. A., & Ramírez, O. T. (2007) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20060216 · Cited by 57
Overview of Humira® Biosimilars: Current European Landscape and Future Implications
Coghlan, J., He, H., & Schwendeman, A. S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.02.003 · Cited by 56
Glyco-engineering for biopharmaceutical production in moss bioreactors
Decker, E. L., Parsons, J., & Reski, R. (2014) · Frontiers in Plant Science · doi:10.3389/fpls.2014.00346 · Cited by 58
“However, lack of this residue proved to be advantageous for the efficacy of antibodies targeting tumor cells (Shields et al., 2002; Shinkawa et al., 2003; Cox et al., 2006; Schuster et al., 2007).”
BackgroundBéliard, R., Waegemans, T., Notelet, D., Massad, L., Dhainaut, F., de Romeuf, C., Guémas, E., Haazen, W., Bourel, D., Teillaud, J., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.06985.x · Cited by 51
“Many reports have focused on the engineering of mAbs using either mutational or glyco-engineering approaches (Thomson et al, 1990; Umana et al, 1999; Shields et al, 2001, 2002; Shinkawa et al, 2003; Teillaud, 2005; Lazar et al, 2006).”
BackgroundTherapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Veomett, N. J., Dao, T., Liu, H., Xiang, J., Pankov, D., Dubrovsky, L., Whitten, J. A., Park, S., Korontsvit, T., Zakhaleva, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2756 · Cited by 55
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
Hasegawa, J., Sue, M., Yamato, M., Ichikawa, J., Ishida, S., Shibutani, T., Kitamura, M., Wada, T., & Agatsuma, T. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235663 · Cited by 56
“Afucosylation of the carbohydrate chain in human Fc has been reported to greatly enhance ADCC by increasing the binding affinity between Fc and FcgRIIIa.31,32 DS-8895a is a novel humanized anti-EPHA2 mAb that is afucosylated to enhance ADCC.”
Core fucose is critical for CD14-dependent Toll-like receptor 4 signaling
Iijima, J., Kobayashi, S., Kitazume, S., Kizuka, Y., Fujinawa, R., Korekane, H., Shibata, T., Saitoh, S.-I., Akashi‐Takamura, S., Miyake, K., et al. (2017) · Glycobiology · doi:10.1093/glycob/cwx075 · Cited by 52
“Furthermore, deletion of core fucose from immunoglobulin G1 (IgG1) markedly improves its binding affinity to Fcγ receptor IIIa, leading to a more than 50-fold increase in antibody-dependent cell-mediated cytotoxicity (Shinkawa et al. 2003; Okazaki et al. 2004).”
BackgroundPonath, P. D., Menezes, D. L. D., Pan, C., Chen, B. Y., Oyasu, M., Strachan, D. C., LeBlanc, H. N., Sun, H., Wang, X.-T., Rangan, V. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0018 · Cited by 55
Darowski, D., Kobold, S., Jöst, C., & Klein, C. (2019) · mAbs · doi:10.1080/19420862.2019.1596511 · Cited by 53
“sylation) of mogamulizumab, a humanized anti-CCR4 IgG1 mAb, improved the binding to FcγRIIIa on activated effector NK cells in the presence of low antigen density.(68) Taken together, these studies demonstrate that FcγRIII modCAR-T cells are able to reliably induce killing in vitro as well as in vivo, in the presence…”
BackgroundProduction of chimeric monoclonal antibodies by genetically manipulated chickens
Kamihira, M., Kawabe, Y., Shindo, T., Ono, K.-I., Esaka, K., Yamashita, T., Nishijima, K.-I., & Iijima, S. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.02.022 · Cited by 51
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology
Li, J., Sai, T., Berger, M., Chao, Q., Davidson, D., Deshmukh, G., Drozdowski, B., Ebel, W., Harley, S., Henry, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511285103 · Cited by 50
Valdez‐Cruz, N. A., García‐Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01576-5 · Cited by 57
Seidel, U. J. E., Vogt, F., Große‐Hovest, L., Jung, G., Handgretinger, R., & Lang, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00618 · Cited by 49
Toyama, A., Nakagawa, H., Matsuda, K., Sato, T., Nakamura, Y., & Ueda, K. (2012) · Analytical Chemistry · doi:10.1021/ac3023372 · Cited by 50
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
Le, N. P. L., Bowden, T. A., Struwe, W. B., & Crispin, M. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.04.016 · Cited by 49
Alga‐Made Anti‐Hepatitis B Antibody Binds to Human Fcγ Receptors
Vanier, G., Stelter, S., Vanier, J., Hempel, F., Maier, U. G., Lerouge, P., Ma, J., & Bardor, M. (2018) · Biotechnology Journal · doi:10.1002/biot.201700496 · Cited by 49
Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function
Gao, R., Sheng, Z., Sreenivasan, C. C., Wang, D., & Li, F. (2020) · Viruses · doi:10.3390/v12030276 · Cited by 50
“It has been demonstrated that the reduced content of fucose can enhance ADCC activity [46].”
BackgroundNovel Treatments of Adult T Cell Leukemia Lymphoma
Hajj, H. E., Tsukasaki, K., Cheminant, M., Bazarbachi, A. A., Watanabe, T., & Hermine, O. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01062 · Cited by 58
“In addition, it highly increases antibody-dependent cellular cytotoxicity because of its reduced fucose (Shinkawa et al., 2003; Ishii et al., 2010).”
BackgroundBoruah, B. M., Kadirvelraj, R., Liu, L., Ramiah, A., Li, C., Zong, G., Bosman, G. P., Yang, J., Wang, L., Boons, G., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014625 · Cited by 49
Lee, S. H., Takahashi, M., Honke, K., Miyoshi, E., Osumi, D., Sakiyama, H., Ekuni, A., Wang, X., Inoué, S., Gu, J., et al. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj039 · Cited by 49
Role of N-Glycosylation in FcγRIIIa interaction with IgG
Coillie, J. V., Schulz, M. A., Bentlage, A. E. H., de Haan, N., Ye, Z., Geerdes, D. M., van Esch, W. J. E., Hafkenscheid, L., Miller, R. L., Narimatsu, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.987151 · Cited by 59
Glyco-engineering of Biotherapeutic Proteins in Plants
Ko, K., Ahn, M., Song, M., Choo, Y., Kim, H. S., Ko, K., & Joung, H. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)17610-2 · Cited by 50
“In plants, β(1,2)xylose and α(1,3)-fucose residues have been shown to be linked to the core Man3GlcNAc2 of glycans, whereas they are not detected on mammalian glycans, where sialic acid residues exist instead (Gomord et al., 2005; Shin et al., 2006 ).”
BackgroundOnitsuka, M., Kim, W.-D., Ozaki, H., Kawaguchi, A., Honda, K., Kajiura, H., Fujiyama, K., Asano, R., Kumagai, I., Ohtake, H., et al. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3814-1 · Cited by 48
“Defucosylation shows a significant increase in binding to FcγRs, resulting in enhancement of ADCC activity (Shinkawa et al. 2003).”
BackgroundChung, C., Wang, Q., Yang, S., Yin, B., Zhang, H., & Betenbaugh, M. (2017) · Biotechnology Journal · doi:10.1002/biot.201600502 · Cited by 48
“For example, antibodies having glycans on the Fc region without the core fucosylation exhibited higher antibody-depend cellular cytotoxicity (ADCC) than its fucosylated counterparts [3, 4].”
BackgroundMartin, T. C., Šimurina, M., Ząbczyńska, M., Kavur, M. M., Rydlewska, M., Pezer, M., Kozłowska, K., Burri, A. V., Vilaj, M. Ć., Turek-Jabrocka, R., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001860 · Cited by 55
Abberant Immunoglobulin G Glycosylation in Rheumatoid Arthritis by LTQ-ESI-MS
Su, Z., Xie, Q., Wang, Y., & Li, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062045 · Cited by 56
“The absence of fucose residues directly boosts ADCC activity by dramatically enhancing binding to FcγRIIIa [37,38].”
BackgroundDesigning proteins for therapeutic applications
Lazar, G. A., Marshall, S. A., Plecs, J. J., Mayo, S. L., & Desjarlais, J. R. (2003) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(03)00104-0 · Cited by 48
Wen, Y., & Jawa, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.003 · Cited by 53
Bryan, L. L. K., CLYNES, M. M., & Meleady, P. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107757 · Cited by 53
Do, K. T., Chow, L. Q. M., Reckamp, K. L., Sanborn, R. E., Burris, H. A., Robert, F., Camidge, D. R., Steuer, C. E., Strickler, J. H., Weise, A. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13911 · Cited by 47
“Afucosylation of the core fucose within the Fc N-glycan domain has also been shown to enhance ADCC [10, 11].”
BackgroundTargeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas
Tobinai, K., Takahashi, T., & Akinaga, S. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0124-3 · Cited by 50
“It is a therapeutic antibody produced using a novel glycoengineering technology that enhances antibodydependent cellular cytotoxic (ADCC) activity [40].”
Background
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.